Racial disparities persist in receipt of curative treatment for early-stage non-small cell lung cancer (NSCLC), according to a study published online March 2 in JAMA Network Open. Olivia F. Lynch, MD, ...

A new study finds Black Medicare beneficiaries with early-stage non–small cell lung cancer (NSCLC) continues to receive curative treatment at lower rates than White patients, highlighting ongoing ...

The company will now assess the available data to determine its next steps in progressing efti’s development across multiple ...

The U.S. Food and Drug Administration (FDA) declined approval of retifanlimab-dlwr for patients with metastatic non-small cell lung cancer (NSCLC) in the United States because of manufacturing ...

Immutep's ASX-listed stock fell more than 88% on the news that its phase 3 trial TACTI-004 of LAG-3 inhibitor eftilagimod alfa (efti) as a first-line treatment for non-small cell lung cancer (NSCLC) ...

A phase 3 study of eftilagimod alfa for NSCLC is ending early due to futility, according to an update from developer Immutep.

Candel Therapeutics Inc (NASDAQ:CADL) is advancing plans to bring its lead cancer immunotherapy toward potential ...

Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual immunotherapy. This episode, titled Dual Immunotherapy Strategies in Metastatic ...

Independent Data Monitoring Committee Recommends Discontinuation of Phase III Trial Following Futility AnalysisSYDNEY, AUSTRALIA, March 13, 2026 ...

Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did ...

Immutep (IMMP) stock plummeted 80% after the company halted its Phase III NSCLC trial for futility, triggering analyst downgrades and massive selling.

Immutep will discontinue a phase three study of its efti drug to treat first-line non-small cell lung cancer following a futility analysis. "We are very disappointed and surprised with the outcome of ...